CDK4 and CDK6 are critical regulators of the cell cycle, and their dysregulation is a common feature in various cancers. Targeting these kinases with specific inhibitors has become a promising therapeutic strategy, particularly in hormone receptor-positive breast cancer, and ongoing research continues to explore their role in other malignancies.
In many cancers, CDK4 and CDK6 are often overexpressed or hyperactivated, leading to uncontrolled cell proliferation.
(Will delete Record if Target field = "Delete") Home